Dr. Rong Fu: Dedicated Exploration – New Insights and Treatments in Aplastic Anemia

Dr. Rong Fu: Dedicated Exploration – New Insights and Treatments in Aplastic Anemia

Aplastic Anemia (AA), a type of bone marrow failure syndrome, is challenging to treat. While hematopoietic stem cell transplantation (HSCT) may offer a cure, it is hindered by donor availability and high risk. Medical treatments provide symptom relief but with limited efficacy and potential for relapse. At the recent 18th Annual Chinese Society of Hematology Conference, Dr. Rong Fu from Tianjin Medical University General Hospital presented valuable insights into immunosuppressive therapy (IST) for AA. Following the conference, Hematology Frontier invited Professor Fu to discuss China’s AA prevalence, diagnostic and treatment advancements, current IST options, and future management strategies.
CSCO 2024 | Dr. Rongbo Lin: POF & POFI Regimens May Set New First-Line Standard for Advanced Gastric Cancer

CSCO 2024 | Dr. Rongbo Lin: POF & POFI Regimens May Set New First-Line Standard for Advanced Gastric Cancer

From September 25 to 29, 2024, the highly anticipated 27th Chinese Clinical Oncology Annual Conference and CSCO Annual Meeting took place in Xiamen. Dr. Rongbo Lin of Fujian Cancer Hospital shared key findings from his team’s research in gastric cancer. During the conference, Oncology Frontier conducted an in-depth interview with Professor Lin, discussing the clinical applications of the POFI and POF regimens for advanced gastric cancer.
SIBCS 2024 | Dr. Li Ma: Advances in Breast Surgery and Pathology Techniques and Prospects for the 2025 “Little Red Book” Updates

SIBCS 2024 | Dr. Li Ma: Advances in Breast Surgery and Pathology Techniques and Prospects for the 2025 “Little Red Book” Updates

At the 2024 SIBCS conference, Dr. Li Ma from The Fourth Hospital of Hebei Medical University presented on the topic “Advances and Controversies in Breast Surgery and Pathology.” He addressed various hot topics, including: “Can axillary dissection be completely avoided in patients with 1–2 positive sentinel lymph nodes? Can axillary dissection be omitted after downstaging lymph nodes with neoadjuvant therapy? Does bilateral mastectomy lower the risk of contralateral cancer but not improve mortality rates? Is screening necessary for HER2-ultra-low expression? What factors influence the accurate diagnosis of HER2-negative and HER2-ultra-low expression?” Following the presentation, Oncology Frontier interviewed Dr. Ma to discuss these advancements and controversies and invited him to share his insights on potential updates in the breast surgery and pathology sections of the 2025 “Little Red Book.”
ILCA 2024 | Dr. Zilin Cui: Milan Criteria vs. Ontario Criteria—A UNOS Analysis

ILCA 2024 | Dr. Zilin Cui: Milan Criteria vs. Ontario Criteria—A UNOS Analysis

In clinical practice, several criteria are available for evaluating liver transplant candidates, such as the Milan Criteria, UCSF Criteria in the U.S., Ontario Criteria in Canada, and domestic standards like the Fudan Criteria and Hangzhou Criteria in China. Among these, the Milan Criteria are the most widely adopted. However, differences in survival outcomes based on these criteria suggest the need for refinement. At the recently held 2024 International Liver Cancer Association (ILCA) Conference, a study utilizing data from the United Network for Organ Sharing (UNOS) compared survival rates between patients evaluated under the Milan Criteria and the Ontario Criteria. Oncology Frontier invited Dr. Zilin Cui from Tianjin First Central Hospital to introduce and review the study.
Dr. Jiuda Zhao Publishes Breakthrough Study in JCO, Demonstrating Electroacupuncture’s Significant Impact on Triple Antiemetic Therapy for Highly Emetogenic Chemotherapy

Dr. Jiuda Zhao Publishes Breakthrough Study in JCO, Demonstrating Electroacupuncture’s Significant Impact on Triple Antiemetic Therapy for Highly Emetogenic Chemotherapy

Recently, the team led by Dr. Jiuda Zhao at the Breast Disease Diagnosis and Treatment Center of Qinghai University Affiliated Hospital published their latest research findings in the Journal of Clinical Oncology (JCO), with an impact factor of 42.10. This study is the first to combine the current standard triple antiemetic therapy with electroacupuncture (EA) to address chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients. The results demonstrate that adding EA to the standard triple antiemetic regimen significantly enhances CINV treatment outcomes. This study stands as the highest-impact acupuncture-related research publication in the field of oncology in China, showcasing the scientific prowess and innovative capabilities of Chinese scholars on the international stage. Oncology Frontier invited Dr. Jiuda Zhao to discuss this groundbreaking study.
CAR-T vs. Bispecific Antibodies: Dr. Junmin Song’s Groundbreaking Myeloma Study at ESMO 2024

CAR-T vs. Bispecific Antibodies: Dr. Junmin Song’s Groundbreaking Myeloma Study at ESMO 2024

The 2024 Annual Meeting of the European Society for Medical Oncology (ESMO) was recently held in Barcelona, Spain. As one of the premier global oncology conferences, it brought together experts and scholars from around the world to share cutting-edge research and chart future directions. During the conference, Dr. Junmin Song from the Jacobi Medical Center, Albert Einstein College of Medicine, presented the first real-world study comparing BCMA CAR-T therapy with bispecific antibodies in the treatment of multiple myeloma (802MO). This presentation garnered significant attention from attendees. Hematology Frontier invited Dr. Song to provide an in-depth interpretation of the study and to discuss the future prospects of these two innovative therapies in multiple myeloma treatment.
CSCO 2024: Dr. Jun Zhu Spearheads China’s Breakthroughs in Anti-Tumor Drug Development

CSCO 2024: Dr. Jun Zhu Spearheads China’s Breakthroughs in Anti-Tumor Drug Development

From September 25 to 29, 2024, the 27th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was successfully held in Xiamen. Themed Patient-Centered, Sharing the Future, the conference brought together major research advancements and developments from both domestic and international spheres. Over the past two decades, CSCO has been a continuous leader in the development of clinical oncology in China, with numerous experts and scholars contributing to and benefiting from CSCO’s growth. In response to CSCO's initiative, Hematology Frontier established the Growing with CSCO column to look back at the history of this organization alongside Chinese scholars. This issue features an exclusive interview with Dr. Jun Zhu, Vice President of the CSCO Council and Professor at Peking University Cancer Hospital, where he shares his journey of growing with CSCO and highlights the progress and achievements in the field of lymphoma in China.
Neo-AEGIS Study Unveils: Peroperative Chemo Stands Tall in Esophageal Cancer Treatment, Signaling a Customized Future

Neo-AEGIS Study Unveils: Peroperative Chemo Stands Tall in Esophageal Cancer Treatment, Signaling a Customized Future

Neo-AEGIS Study Unveils: Peroperative Chemo Stands Tall in Esophageal Cancer Treatment, Signaling a Customized Future Editor's Note: From September 22nd to 24th, 2024, the 20th International Esophageal Cancer Conference (ISDE) took place in Edinburgh, Scotland. The Neo-AEGIS study, which compared the efficacy of perioperative chemotherapy with the CROSS regimen (preoperative chemotherapy combined with radiotherapy) in the treatment of esophageal cancer, captured global attention. As the corresponding author of the study, Dr. John Reynolds from St. James's Hospital in Ireland provided an in-depth interpretation of the research findings and discussed their profound impact on future strategies for esophageal cancer treatment.
CSCO 2024 Visionary: Dr. Jun Zhou Illuminates the Path Forward for Biliary Tract Cancer Treatment

CSCO 2024 Visionary: Dr. Jun Zhou Illuminates the Path Forward for Biliary Tract Cancer Treatment

From September 25 to 29, 2024, the highly anticipated 27th National Clinical Oncology Conference and CSCO Annual Meeting was successfully held in Xiamen. This prestigious event brought together top experts in the field of oncology from across China, focusing on standardized pathways for diagnosis and treatment of malignant tumors and exploring the latest frontiers. During the conference, Dr. Jun Zhou from Peking University Cancer Hospital delivered a presentation titled “Advances in the Application of New Anticancer Drugs in Biliary Tract Cancer” at the dedicated session on targeted therapy for cholangiocarcinoma. Oncology Frontier had the opportunity to conduct an in-depth interview with Professor Zhou, delving into the current progress in drug treatments for biliary tract cancers and exploring future research directions.